Navigation Links
ARX-01 and ARX-03 Clinical Results Presented at the 30th Annual Scientific Meeting of the American Pain Society
Date:5/18/2011

ia for patients undergoing painful office-based procedures.  Neil Singla, MD of Lotus Clinical Research in Pasadena, CA will present data from 40 patients who underwent elective low-volume liposuction.  Administration of ARX-03 produced mild sedation and anxiolysis with rapid onset of effect, high physician and patient evaluations of effectiveness and tolerability, and a low incidence of side effects.  Copies of these abstracts are available from the AcelRx Pharmaceuticals web site at www.acelrx.com/technology/publications.

About AcelRx Pharmaceuticals, Inc.

Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab(R) PCA System, which has completed Phase 2 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA) which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' statements related to clinical trial updates, effectiven
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
2. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Calif. , June 30, 2015  Ardelyx, Inc. ... on cardio-renal, gastrointestinal and metabolic diseases, today announced that ... July 14, 2015, from 8:00 a.m.- 1:00 pm EDT ... The Ardelyx senior management team will present ... lead compound, tenapanor, which has completed Phase 2b clinical ...
(Date:6/30/2015)... , BERKELEY, Kalifornien, und KOPENHAGEN, Dänemark, ... Biologics, Inc. , ein Weltmarktführer der klinischen ... anderen therapeutischen Proteinen, gab heute bekannt, dass ... der Produktionskapazität den Ausbau der nordamerikanischen Produktionsanlage ... mit der Ergänzung  einer Einweg-Anlage Bioreactor 6Pack™ ...
(Date:6/30/2015)... , June 24, 2015 Research ... of the "Global Endoscopy Devices Market 2015-2019" ... global endoscopy devices market to grow at a ... The global endoscopy devices market can be segmented ... accessories, and services. The market can be further ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 2Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 3
... (Nasdaq: ISIS ), the leader in antisense therapeutics, ... Stifel Nicolaus, Healthcare Conference 2011 on Thursday, September 08, 2011 ... Boston. A live audio webcast of the presentation ... the Company,s Web site, www.isispharm.com .  A replay of ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... Company,s participation at the William Blair and Company 5th Annual ... Hotel in New York City on September 8, 2011. ... Research and Development, will present on Thursday, September 8, 2011 ...
Cached Medicine Technology:Sequenom Announces Participation at William Blair and Company 5th Annual Emerging Growth Stock Conference 2
(Date:6/30/2015)... ... June 30, 2015 , ... Lakeview ... more than doubled the size of its medical staff to further enhance its ... which includes physicians, nurse practitioners and physician assistants -- now totals 17, compared ...
(Date:6/30/2015)... Plains, NJ (PRWEB) , ... June 30, 2015 , ... ... Techniques, they will be wowed with the incredible care that they receive and the ... care for their patients; but now they are proud to offer the same experience, ...
(Date:6/30/2015)... ... ... The U.S. Women's National Soccer Team will face the Costa Rica Women's National team ... August 16th at Heinz Field in Pittsburgh at 1:30 p.m. local time. On Wednesday, ... TN. , The USA WNT previously played at Heinz Field in Pittsburgh and won against ...
(Date:6/30/2015)... NY (PRWEB) , ... June 30, 2015 , ... ... newest oncology centers are partnering to improve access to cancer prevention, screening and ... Cancer Center (LCC) have announced an affiliation that will see Roswell Park faculty ...
(Date:6/30/2015)... ... June 30, 2015 , ... After more than five years ... Drug Administration, GlobalSun (TM) — sunscreen specifically formulated for the unique skin of all ... 35, hits the market just in time to help protect the skin of all ...
Breaking Medicine News(10 mins):Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 3Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 4Health News:USA vs. Costa Rica Tickets at Heinz Field in Pittsburgh and Finley Stadium in Chattanooga: Ticket Down Slashes Presale Ticket Prices for Costa Rica vs. USA WNT 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2
... Conference on Cell Therapy for Cardiovascular Disease sponsored ... comprehensive program dedicated to the evolving field of ... cardiac and vascular disease, as well as related ... conference will focus on preclinical and clinical studies ...
... The March of Dimes, along with its partners, are giving ... to learn from each other and to work together to ... give more babies a healthy start. U.S. Surgeon ... Prevention Symposium. The symposium will was a forum to share ...
... of researchers has discovered 13 new regions of the genome ... on the biological pathways involved in reproductive lifespan and will ... cancer and heart disease. Menopause is a ... in their early 50s. The timing of menopause can have ...
... Kathleen Doheny HealthDay Reporter , SUNDAY, Jan. ... genomic regions they believe are linked with breast cancer ... disease. All three newly identified areas "contain interesting ... clinical research," said researcher Douglas Easton, a professor of ...
... 2012) Research to Prevent Blindness (RPB) has awarded ... School, a $30,000 Medical Student Eye Research Fellowship. The award ... award will allow Ms. Shah to participate in research under ... Dr. Louis Pasquale in collaboration with Dr. Suzanne Freitag, Director ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, Jan. ... moratorium on controversial research into a modified avian flu virus ... Although the investigators believe their research has a public ... others that the genetically altered virus could escape from labs ...
Cached Medicine News:Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 2Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 3Health News:March of Dimes launches Prematurity Prevention Network 2Health News:March of Dimes launches Prematurity Prevention Network 3Health News:Genes and timing of menopause 2Health News:New Genetic Clues to Breast Cancer? 2Health News:New Genetic Clues to Breast Cancer? 3Health News:Scientists Agree to Delay Controversial Bird Flu Research 2Health News:Scientists Agree to Delay Controversial Bird Flu Research 3
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... 2.2 offers extremely high resolution treatment capability ... an exceptionally wide 78° field of view. ... critical evaluation of the optic nerve head ... of the macula and disc. Redesigned to ...
... for focal laser therapy and mid-to-far peripheral ... a realistic contour of the retinal concavity, ... entire posterior pole extending to the equator. ... dynamic movement on the globe, therefore increasing ...
... The Digital 1.0x Imaging Lens is optimized ... reduce glare and reflections during general diagnosis and ... view of the posterior pole and a sharper ... Digital 1.0 X Imaging Lens is also ideal ...
Medicine Products: